Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC

Background This study aimed to compare the efficacy of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) combined with low-dose bevacizumab(7.5 mg/kg) versus osimertinib as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer...

Full description

Saved in:
Bibliographic Details
Main Authors: Yingqi Xu, Yidan Zhang, Hongping Jin, Hua Zhong, Jianlin Xu, Yuqing Lou, Runbo Zhong
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Annals of Medicine
Subjects:
Bevazicumab
EGFR-TKI
low-dose
NSCLC
osimertinib
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2025.2493766
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items